Skip to content
Briefings are running a touch slower this week while we rebuild the foundations.See roadmap
Pandemics and Biosecurity
24MAY

B3.13 replicates better in human nasal tissue

4 min read
16:06UTC

NIH/NIAID researchers Flagg and Winski published peer-reviewed evidence on 12 May that the H5N1 strain dominating US dairy cattle replicates more efficiently in human nasal epithelium than any historical H5N1 strain and partly disables the immune alarm that would normally limit early replication.

ScienceDeveloping
Key takeaway

B3.13 outperforms historical H5N1 in human nasal tissue and delays the immune alarm, while surveillance weakens.

NIH/NIAID researchers Flagg and Winski published a study in CDC Emerging Infectious Diseases (DOI: 10.3201/eid3205.260053) on 12 May showing that B3.13 (the clade 2.3.4.4b H5N1 genotype circulating in US dairy cattle since 2024) replicates more efficiently in human nasal epithelium cultures than historical H5N1 strains. 1 The same paper found that B3.13 suppresses ISG (interferon-stimulated gene) responses, the innate immune system's first-line molecular alarm; a virus that triggers fewer ISGs buys more time to replicate before the body mounts a coordinated defence.

The Emory University aerosol study published in PLOS Biology on 1 May had already shown B3.13 present in submicron aerosol particles inside milking-parlour air across 14 California farms . Together, the two papers complete a mechanistic two-step pathway: B3.13 reaches the nasal epithelium via the aerosol route, and once there it replicates efficiently while partially evading innate immunity. Neither paper claims human-to-human transmission is imminent. What they jointly establish is a directional fitness signal that the 2024-era virological profile of B3.13 did not contain.

The EID paper also found that 66% of exposed dairy farm workers carried pre-existing neutralising antibodies against pdm09 H1N1 (the pandemic H1N1 strain from 2009, now endemic globally as a seasonal influenza). 2 The researchers suggest this cross-immunity may explain why the CDC human case counter has stood at 71 since 6 March, even as the national dairy cattle total crossed 1,047 cases in 17 states. That explanation carries a corollary: workers WHO missed 2009 pandemic vaccination or WHO received only attenuated protection carry reduced cover if human spread accelerates.

The ISG suppression mechanism adds a clinical-detection wrinkle. ISG induction produces the fever and cytokine symptoms that typically prompt dairy workers to seek testing; a strain that delays ISG activation could circulate longer before self-reporting, compressing the window between exposure and detection. Bangladesh and Cambodia logged four human H5N1 cases by February, all from poultry contact , confirming the dairy-cattle route to human exposure remains less documented. The defensive side has one concrete advance: CEPI's (Coalition for Epidemic Preparedness Innovations) mRNA H5N1 vaccine candidate entered Phase 3 trial on 22 April , the furthest any such candidate has reached.

Deep Analysis

In plain English

**H5N1** is a bird flu virus that has been spreading through US dairy cattle since 2024. Scientists were worried about whether it could infect humans more easily, and this new study answers part of that question. Researchers at the **National Institute of Allergy and Infectious Diseases** grew human nasal cells in a lab and exposed them to the specific strain called **B3.13** that lives in US dairy herds. They found it copied itself more efficiently in those cells than older bird flu strains did, and it also partially switched off the cells' first alarm signal (the immune response that normally slows a virus down). The reassuring part: about two-thirds of dairy farm workers already have leftover immune protection from the 2009 swine flu pandemic. Scientists think this is probably why human cases have stayed rare even though the virus has been improving at getting into human nose cells. The worry is that this protection will not last forever, especially as the virus keeps spreading across more herds.

Deep Analysis
Root Causes

Three structural conditions combine to produce this finding. First, B3.13 evolved in the **mammary epithelium** of dairy cattle, a tissue environment that shares sialic acid receptor distribution with human nasal epithelium, creating inadvertent selective pressure for human nasal-compatible variants without any direct human infection required.

Second, the ISG suppression pathway B3.13 uses is the same interferon-evasion strategy seen in multiple pandemic-capable strains. The **NIAID/NIH** team's finding that B3.13 suppresses ISG responses below historical H5N1 levels is not a random mutation; it reflects cumulative selection across two years of continuous dairy-herd circulation.

Third, the surveillance architecture that might catch an early human adaptation event was partially dismantled on 1 May 2026 when **USDA APHIS** ended mandatory interstate testing, removing the movement-checkpoint layer that historically detected infections before they crossed state lines.

What could happen next?
  • Risk

    If B3.13 acquires mutations that allow it to partially evade pdm09 antibodies, the 66% workforce-immunity buffer collapses and occupational exposure converts from rare to frequent.

    Medium term · 0.65
  • Consequence

    CDC and USDA face regulatory pressure to revise dairy-worker PPE guidance to include N95 respirators for milking operations, following the Emory aerosol evidence (ID:3109) and now nasal-fitness confirmation.

    Short term · 0.75
  • Precedent

    The EID paper establishes nasal-epithelium culture assays as the standard B3.13 fitness benchmark, meaning future variant comparisons will be assessed against this baseline.

    Long term · 0.8
First Reported In

Update #2 · B3.13 gets better at humans as testing ends

CDC Emerging Infectious Diseases· 12 May 2026
Read original
Causes and effects
This Event
B3.13 replicates better in human nasal tissue
The first mechanistic characterisation of B3.13 in human nasal tissue establishes a fitness trajectory that surveillance infrastructure is no longer fully equipped to track.
Different Perspectives
European Union / ECDC
European Union / ECDC
ECDC activated an EU Health Task Force, assessed European Bundibugyo import risk as very low, and flagged the recombinant clade Ib/IIb mpox strain in four countries as a surveillance watch item. Both calls reflect the same post-2024 IHR mandate: ECDC acts as a continental early-warning layer rather than waiting for WHO Disease Outbreak News guidance.
Ituri and South Kivu communities / DRC
Ituri and South Kivu communities / DRC
Residents in South Kivu torched a treatment facility when response teams arrived, a signal of community trust deficit that a no-state-apparatus response cannot overcome before it can begin. In Ituri, four healthcare worker deaths at Mongbwalu General Referral Hospital in four days reflect the population's first line of care bearing the outbreak's worst nosocomial burden without species-specific equipment or treatment.
Uganda / Diana Atwine
Uganda / Diana Atwine
Atwine confirmed two imported Bundibugyo cases in Kampala with no onward spread, deployed a mobile laboratory to Kasese on the DRC border, and placed 25 contacts under monitoring before any IHR Temporary Recommendations existed. Uganda's response demonstrates that containment is achievable where a functioning state health authority can compel and protect.
Africa CDC / Jean Kaseya
Africa CDC / Jean Kaseya
Kaseya declared a continental emergency 24 hours before the WHO PHEIC and publicly opposed the US entry ban on 19 May, arguing it punishes countries by passport rather than exposure history. The declaration, Africa CDC's second consecutive pre-WHO move after the 2024 mpox sequencing, reflects an AU strategy to lead early-phase responses independently of Geneva.
United States / HHS
United States / HHS
Washington imposed a 21-day entry ban on nationals of DRC, Uganda and South Sudan on 18 May, including green-card holders, and began enhanced screening for US citizens at George Bush Intercontinental Airport in Houston from 26 May. The ban predated WHO Temporary Recommendations by four days and covered South Sudan despite zero confirmed cases there.
Tedros Adhanom Ghebreyesus / WHO
Tedros Adhanom Ghebreyesus / WHO
Tedros declared the PHEIC on 17 May without the IHR Emergency Committee, then watched the committee's 22 May no-travel-restriction advice arrive four days after the US ban it was meant to prevent. A declaration without operational instructions left states parties with the headline of a global emergency but no guidance on screening, trade or deployment.